COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 micrograms)/dose, injectable dispersion. mRNA vaccine (nucleoside-modified) against COVID-19 60 doses
Active ingredients: FAMTOZINAMÉRAN, TOZINAMÉRAN
Commercialized according to BDPMDispensing in France: Prescription only
Injectable dispersion60 dosesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 microgrammes)/dose, dispersion injectable. Vaccin à ARNm (à nucléoside modifié) contre la COVID-19
- Pharmaceutical form
- dispersion injectable
- Route of administration
- intramusculaire
- Presentation description
- 10 flacon(s) multidose(s) en verre de 6 dose(s) ( abrogée le 12/12/2024)
- Marketing authorisation holder
- BIONTECH MANUFACTURING (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 19 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65590890CIP73026200CIP133400930262009Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FAMTOZINAMÉRANdispersion | 15 microgrammes · une dose de 0,3 mL | SA |
| TOZINAMÉRANdispersion | 15 microgrammes · une dose de 0,3 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.